First evidence of significant clinical activity of PD1 inhibition in metastatic prostate cancer

Share :
Published: 17 Oct 2016
Views: 2873
Dr Julie Graff - Knight Cancer Institute, Oregon Health & Science University, Portland, USA

Dr Graff speaks with ecancertv at ESMO 2016 about her research, finding the first significant response of men with metastatic castration-resistant prostate cancer to PD-1 targetted therapy.

She describes how this challenges prior results of prostate cancer as a 'cold tumour', resistant to immunotherapy, and opens the way to new treatment pathways for men who have few therapeutic options.

Dr Graff also considers the positioning of PD-1 modulation as a front line therapy, as discussed by Dr Arjun Balar here.